These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 30144258)

  • 1. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey.
    Shaffer AA; Thomas AG; Bowring MG; Van Pilsum Rasmussen SE; Cash A; Kucirka LM; Alqahtani SA; Gurakar A; Sulkowski MS; Cameron AM; Segev DL; Durand CM
    Transpl Infect Dis; 2018 Dec; 20(6):e12982. PubMed ID: 30144258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States.
    Bowring MG; Shaffer AA; Massie AB; Cameron A; Desai N; Sulkowski M; Garonzik-Wang J; Segev DL
    Am J Transplant; 2019 Aug; 19(8):2329-2341. PubMed ID: 30861279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should organs from hepatitis C-positive donors be used in hepatitis C-negative recipients for liver transplantation?
    Selzner N; Berenguer M
    Liver Transpl; 2018 Jun; 24(6):831-840. PubMed ID: 29624894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus-Viremic Livers.
    Mazur RD; Goldberg DS
    Liver Transpl; 2019 Dec; 25(12):1800-1810. PubMed ID: 31539195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
    Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
    Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing repeat liver transplant graft utility through strategic matching of donor and recipient characteristics.
    Hung K; Gralla J; Dodge JL; Bambha KM; Dirchwolf M; Rosen HR; Biggins SW
    Liver Transpl; 2015 Nov; 21(11):1365-73. PubMed ID: 25865434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective.
    Saab S; Kardashian A; Saggi S; Choi G; Agopian V; Tong MJ
    Clin Transplant; 2018 Oct; 32(10):e13383. PubMed ID: 30129981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report.
    Said A; Weiss M; Varhelyi A; Farago R; Ballweg C; Rice J; Agarwal P; Fernandez L; Foley D
    Transpl Infect Dis; 2021 Apr; 23(2):e13466. PubMed ID: 32931616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.
    Chhatwal J; Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DM; Chung RT
    Hepatology; 2017 Mar; 65(3):777-788. PubMed ID: 27906468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients.
    Belli LS; Duvoux C; Berenguer M; Berg T; Coilly A; Colle I; Fagiuoli S; Khoo S; Pageaux GP; Puoti M; Samuel D; Strazzabosco M
    J Hepatol; 2017 Sep; 67(3):585-602. PubMed ID: 28323126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.
    Aqel B; Wijarnpreecha K; Pungpapong S; Taner CB; Reddy K; Leise M; Mi L; Dickson RC
    J Hepatol; 2021 Apr; 74(4):873-880. PubMed ID: 33188903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of hepatitis C treatment clinical practice patterns using the newly approved protease inhibitors.
    Chen EY; Lee WM; Hynan LS; Singal AG
    J Clin Gastroenterol; 2013 Oct; 47(9):800-6. PubMed ID: 23470640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of hepatitis C virus infected donors in heart transplant recipients with elevated MELD-XI score.
    Hirani R; Okumura K; Isath A; Gregory V; Khan S; Dhand A; Lanier GM; Spielvogel D; Kai M; Ohira S
    Clin Transplant; 2023 Dec; 37(12):e15124. PubMed ID: 37688341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplant recipients and prioritization of anti-HCV therapy: an Italian cohort analysis.
    Lanini S; Nanni Costa A; Grossi PA; Procaccio F; Ricci A; Capobianchi MR; Terrault NA; Ippolito G
    Liver Int; 2016 Mar; 36(3):410-7. PubMed ID: 26264452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
    Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
    Liver Transpl; 2019 Apr; 25(4):598-609. PubMed ID: 30716208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
    Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
    J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy.
    Bowring MG; Kucirka LM; Massie AB; Ishaque T; Bae S; Shaffer AA; Garonzik Wang J; Sulkowski M; Desai N; Segev DL; Durand CM
    Transplantation; 2018 Dec; 102(12):2088-2095. PubMed ID: 29912046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation.
    Cotter TG; Aronsohn A; Reddy KG; Charlton M
    Transplantation; 2021 Jun; 105(6):1285-1290. PubMed ID: 32639400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.